Performance of Hong Kong Liver Cancer staging system in patients of hepatocellular carcinoma treated with surgical resection: An Indian validation study.
Adolescent
Adult
Aged
Aged, 80 and over
Carcinoma, Hepatocellular
/ surgery
Female
Follow-Up Studies
Hepatectomy
/ mortality
Humans
India
Liver Neoplasms
/ pathology
Male
Middle Aged
Neoplasm Recurrence, Local
/ pathology
Neoplasm Staging
Prospective Studies
ROC Curve
Retrospective Studies
Survival Rate
Young Adult
HCC staging systems
HKLCS system vs BCLCS system stagin
TACE
liver resection in HCC
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
21
07
2019
accepted:
03
09
2019
pubmed:
25
9
2019
medline:
13
11
2019
entrez:
25
9
2019
Statut:
ppublish
Résumé
Hong Kong Liver Cancer staging (HKLCS) system lacks external validation. We conducted a study to validate the prognostic and clinical utility of HKLCS system in the patients with hepatocellular carcinoma (HCC) of heterogeneous etiologies treated with hepatic resection with curative intent at Tata Memorial Centre, Mumbai, India. A total of 144 patients underwent resection for HCC. Our patient cohort was comparable to the original developmental cohort in median age and gender distribution but differed in etiology, liver function status, and tumor venous invasion. On Kaplan-Meier survival curve analysis for overall and disease-free survival, we could achieve statistically significant separation of curves in both Barcelona Clinic Liver Cancer staging (BCLCS) and HKLCS staging systems (P < .000). Interstage discrimination between early and intermediate stages for survival was higher in HKLCS system (P value of .039 vs .091). The area under the receiver operating characteristic curve for the survival of BCLCS and HKLCS systems for the entire patient population was 0.66 and 0.60, respectively, which was not statistically significant (P = .31). The HKLCS system offered higher interstage discrimination power in the patients with HCC treated with resection and may be equally applicable to nonalcoholic steatosis-related chronic liver disease and noncirrhotic patient population.
Sections du résumé
BACKGROUND
BACKGROUND
Hong Kong Liver Cancer staging (HKLCS) system lacks external validation.
AIMS AND METHODS
OBJECTIVE
We conducted a study to validate the prognostic and clinical utility of HKLCS system in the patients with hepatocellular carcinoma (HCC) of heterogeneous etiologies treated with hepatic resection with curative intent at Tata Memorial Centre, Mumbai, India.
RESULTS
RESULTS
A total of 144 patients underwent resection for HCC. Our patient cohort was comparable to the original developmental cohort in median age and gender distribution but differed in etiology, liver function status, and tumor venous invasion. On Kaplan-Meier survival curve analysis for overall and disease-free survival, we could achieve statistically significant separation of curves in both Barcelona Clinic Liver Cancer staging (BCLCS) and HKLCS staging systems (P < .000). Interstage discrimination between early and intermediate stages for survival was higher in HKLCS system (P value of .039 vs .091). The area under the receiver operating characteristic curve for the survival of BCLCS and HKLCS systems for the entire patient population was 0.66 and 0.60, respectively, which was not statistically significant (P = .31).
CONCLUSION
CONCLUSIONS
The HKLCS system offered higher interstage discrimination power in the patients with HCC treated with resection and may be equally applicable to nonalcoholic steatosis-related chronic liver disease and noncirrhotic patient population.
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1119-1125Informations de copyright
© 2019 Wiley Periodicals, Inc.